NO20130265A1 - Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser - Google Patents

Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser Download PDF

Info

Publication number: NO20130265A1
Authority: NO; Norway
Prior art keywords: activated; seq; pharmaceutical preparation; antibody against; insulin receptor
Prior art date: 2010-07-21

Application number

NO20130265A

Other languages

English (en)

Norwegian (no)

Inventor

Oleg Iliich Epshtein

Original Assignee

Oleg Iliich Epshtein

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-21

Filing date

2013-02-18

Publication date

2013-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20130265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-07-21 Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru

2011-07-01 Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru

2013-02-18 Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein

2013-04-18 Publication of NO20130265A1 publication Critical patent/NO20130265A1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Alternative & Traditional Medicine (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20130265A 2010-07-21 2013-02-18 Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser NO20130265A1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
RU2010130348/15A RU2531048C2 (ru)	2010-07-21	2010-07-21	Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru)	2011-07-01	2011-07-01	Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002177 WO2012010966A2 (fr)	2010-07-21	2011-07-15	Composition pharmaceutique combinée, et procédés de traitement du diabète et de troubles métaboliques

Publications (1)

Publication Number	Publication Date
NO20130265A1 true NO20130265A1 (no)	2013-04-18

Family

ID=44899155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20130265A NO20130265A1 (no)	2010-07-21	2013-02-18	Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser

Country Status (30)

Country	Link
US (1)	US8617555B2 (fr)
EP (2)	EP2595658A2 (fr)
JP (2)	JP2013533268A (fr)
KR (2)	KR20130103486A (fr)
CN (1)	CN103118707A (fr)
AR (1)	AR082312A1 (fr)
AU (1)	AU2011281240B2 (fr)
BR (1)	BR112013001299A2 (fr)
CA (1)	CA2805961A1 (fr)
CL (1)	CL2013000200A1 (fr)
CZ (1)	CZ2013124A3 (fr)
DE (1)	DE112011102396T5 (fr)
DK (1)	DK201370089A (fr)
EA (1)	EA029847B1 (fr)
EE (1)	EE05761B1 (fr)
ES (1)	ES2445846R1 (fr)
FI (1)	FI20135152L (fr)
FR (1)	FR2962913A1 (fr)
GB (2)	GB2552405B (fr)
IT (1)	ITTO20110627A1 (fr)
LT (1)	LT5980B (fr)
MX (1)	MX2013000804A (fr)
MY (1)	MY160979A (fr)
NO (1)	NO20130265A1 (fr)
NZ (1)	NZ606964A (fr)
PE (1)	PE20130815A1 (fr)
PH (1)	PH12013500140A1 (fr)
SE (1)	SE1350212A1 (fr)
SG (1)	SG187578A1 (fr)
WO (1)	WO2012010966A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2181297C2 (ru) *	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en)	2002-08-02	2006-08-15	Oleh Illich Epshtein	Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) *	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2654408C (fr) *	2006-06-06	2018-05-08	Oleg Iliich Epshtein	Preparation medicamenteuse destinee au traitement peroral de l'exces ponderal, du diabete sucre et de maladies accompagnees d'une perturbation de la tolerance du glucose
FR2962652A1 (fr)	2010-07-15	2012-01-20	Oleg Iliich Epshtein	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
MX2013000543A (es) *	2010-07-15	2013-10-28	Oleg Iliich Epshtein	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
EA029400B1 (ru)	2010-07-15	2018-03-30	Олег Ильич ЭПШТЕЙН	Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
FR2962909A1 (fr) *	2010-07-21	2012-01-27	Oleg Iliich Epshtein	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
US20130058981A1 (en) *	2010-07-21	2013-03-07	Oleg Iliich Epshtein	Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
PH12013500144A1 (en)	2010-07-21	2018-03-21	Oleg Iliich Epshtein	A method of treating attention deficit hyperactivity disorder
CZ2013159A3 (cs) *	2010-08-06	2013-06-12	Iliich Epshtein@Oleg	Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob
TWI588153B (zh) *	2012-05-18	2017-06-21	中國醫藥大學	多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru)	2013-03-18	2014-09-27	Олег Ильич Эпштейн	Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru)	2013-03-18	2014-09-27	Олег Ильич Эпштейн	Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4311897A (en)	1979-08-28	1982-01-19	Union Carbide Corporation	Plasma arc torch and nozzle assembly
US5811437A (en) *	1996-05-21	1998-09-22	Eli Lilly And Company	Methods of increasing nitric oxide synthesis
US6150500A (en) *	1996-07-12	2000-11-21	Salerno; John C.	Activators of endothelial nitric oxide synthase
WO1999026657A1 (fr) *	1997-11-25	1999-06-03	Musc Foundation For Research Development	Inhibiteurs de la monoxyde d'azote-synthase
US6933272B1 (en) *	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) *	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en)	2002-08-02	2006-08-15	Oleh Illich Epshtein	Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
AU2003262804A1 (en) *	2002-08-22	2004-03-11	Nutrition 21, Inc.	Arginine silicate inositol complex and use thereof
GB2414670B (en)	2003-03-14	2008-03-19	Nutrition Res Inc	Homeopathic formulations useful for treating pain and/or inflammation
KR20060125849A (ko) *	2004-01-20	2006-12-06	아스텔라스세이야쿠 가부시키가이샤	발기부전 치료 방법
CA2654408C (fr) *	2006-06-06	2018-05-08	Oleg Iliich Epshtein	Preparation medicamenteuse destinee au traitement peroral de l'exces ponderal, du diabete sucre et de maladies accompagnees d'une perturbation de la tolerance du glucose
RU2438707C2 (ru) *	2006-06-06	2012-01-10	Олег Ильич Эпштейн	Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) *	2008-07-02	2008-08-06	Asterion Ltd	Insulin
EA029400B1 (ru) *	2010-07-15	2018-03-30	Олег Ильич ЭПШТЕЙН	Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
MX2013000543A (es) *	2010-07-15	2013-10-28	Oleg Iliich Epshtein	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962652A1 (fr) *	2010-07-15	2012-01-20	Oleg Iliich Epshtein	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
FR2962909A1 (fr) *	2010-07-21	2012-01-27	Oleg Iliich Epshtein	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
US20130058981A1 (en) *	2010-07-21	2013-03-07	Oleg Iliich Epshtein	Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

2011
- 2011-07-15 CN CN2011800454899A patent/CN103118707A/zh active Pending
- 2011-07-15 CZ CZ20130124A patent/CZ2013124A3/cs unknown
- 2011-07-15 MX MX2013000804A patent/MX2013000804A/es active IP Right Grant
- 2011-07-15 ES ES201390009A patent/ES2445846R1/es active Pending
- 2011-07-15 KR KR1020137004330A patent/KR20130103486A/ko not_active Ceased
- 2011-07-15 WO PCT/IB2011/002177 patent/WO2012010966A2/fr not_active Ceased
- 2011-07-15 SG SG2013004817A patent/SG187578A1/en unknown
- 2011-07-15 US US13/135,891 patent/US8617555B2/en active Active
- 2011-07-15 EP EP11773314.7A patent/EP2595658A2/fr not_active Ceased
- 2011-07-15 DE DE112011102396T patent/DE112011102396T5/de not_active Withdrawn
- 2011-07-15 FR FR1156480A patent/FR2962913A1/fr not_active Withdrawn
- 2011-07-15 JP JP2013520235A patent/JP2013533268A/ja active Pending
- 2011-07-15 IT IT000627A patent/ITTO20110627A1/it unknown
- 2011-07-15 GB GB1707872.6A patent/GB2552405B/en not_active Expired - Fee Related
- 2011-07-15 PH PH1/2013/500140A patent/PH12013500140A1/en unknown
- 2011-07-15 KR KR1020187032943A patent/KR20180127515A/ko not_active Ceased
- 2011-07-15 EA EA201300124A patent/EA029847B1/ru not_active IP Right Cessation
- 2011-07-15 GB GB1302924.4A patent/GB2496799B/en not_active Expired - Fee Related
- 2011-07-15 PE PE2013000114A patent/PE20130815A1/es not_active Application Discontinuation
- 2011-07-15 FI FI20135152A patent/FI20135152L/fi not_active Application Discontinuation
- 2011-07-15 AU AU2011281240A patent/AU2011281240B2/en not_active Ceased
- 2011-07-15 NZ NZ606964A patent/NZ606964A/en not_active IP Right Cessation
- 2011-07-15 SE SE1350212A patent/SE1350212A1/sv unknown
- 2011-07-15 EP EP19213849.3A patent/EP3693018A1/fr not_active Withdrawn
- 2011-07-15 BR BR112013001299A patent/BR112013001299A2/pt not_active Application Discontinuation
- 2011-07-15 CA CA2805961A patent/CA2805961A1/fr not_active Abandoned
- 2011-07-15 EE EEP201300007A patent/EE05761B1/et not_active IP Right Cessation
- 2011-07-15 MY MYPI2013000225A patent/MY160979A/en unknown
- 2011-07-21 AR ARP110102642A patent/AR082312A1/es not_active Application Discontinuation
2013
- 2013-01-21 CL CL2013000200A patent/CL2013000200A1/es unknown
- 2013-02-18 NO NO20130265A patent/NO20130265A1/no not_active Application Discontinuation
- 2013-02-19 LT LT2013018A patent/LT5980B/lt not_active IP Right Cessation
- 2013-02-19 DK DKPA201370089A patent/DK201370089A/da not_active Application Discontinuation
2016
- 2016-07-01 JP JP2016131729A patent/JP2016222684A/ja active Pending

Also Published As

Publication number	Publication date
CL2013000200A1 (es)	2015-01-23
KR20180127515A (ko)	2018-11-28
LT5980B (lt)	2013-12-27
JP2016222684A (ja)	2016-12-28
AU2011281240A1 (en)	2013-03-07
EE05761B1 (et)	2016-03-15
CN103118707A (zh)	2013-05-22
FI20135152A7 (fi)	2013-02-21
DE112011102396T5 (de)	2013-05-02
FR2962913A1 (fr)	2012-01-27
EA201300124A1 (ru)	2013-12-30
JP2013533268A (ja)	2013-08-22
ES2445846A2 (es)	2014-03-05
US8617555B2 (en)	2013-12-31
ES2445846R1 (es)	2015-01-02
EP3693018A1 (fr)	2020-08-12
ITTO20110627A1 (it)	2012-01-22
US20130064824A1 (en)	2013-03-14
NZ606964A (en)	2015-08-28
AU2011281240B2 (en)	2016-07-07
SE1350212A1 (sv)	2013-04-22
GB2552405B (en)	2018-05-30
GB201302924D0 (en)	2013-04-03
BR112013001299A2 (pt)	2017-11-21
PE20130815A1 (es)	2013-07-18
DK201370089A (en)	2013-02-19
PH12013500140A1 (en)	2013-03-11
EA029847B1 (ru)	2018-05-31
GB2496799B (en)	2017-11-22
MY160979A (en)	2017-03-31
AR082312A1 (es)	2012-11-28
MX2013000804A (es)	2013-10-28
FI20135152L (fi)	2013-02-21
SG187578A1 (en)	2013-03-28
WO2012010966A3 (fr)	2012-03-29
WO2012010966A2 (fr)	2012-01-26
EP2595658A2 (fr)	2013-05-29
CA2805961A1 (fr)	2012-01-26
LT2013018A (lt)	2013-10-25
CZ2013124A3 (cs)	2013-06-12
GB201707872D0 (en)	2017-06-28
EE201300007A (et)	2013-08-15
GB2496799A (en)	2013-05-22
GB2552405A (en)	2018-01-24
KR20130103486A (ko)	2013-09-23

Publication	Publication Date	Title
NO20130265A1 (no)	2013-04-18	Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser
AU2011278039B2 (en)	2015-07-23	A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
FR2962652A1 (fr)	2012-01-20	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
US20130064860A1 (en)	2013-03-14	Combination pharmaceutical composition and methods of theating genitourinary system disorders
EP2596019A2 (fr)	2013-05-29	Procédé de traitement du trouble de l'attention avec hyperactivité
MX2013001450A (es)	2013-10-25	Composicion farmaceutica y metodo para inhibir la produccion o amplificar la eliminacion de la proteina p24.
MX2013000543A (es)	2013-10-28	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
AU2002242273B2 (en)	2007-12-13	Compositions of multimeric profilin for diagnosis and treatment of allergies
RU2531048C2 (ru)	2014-10-20	Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2565401C2 (ru)	2015-10-20	Способ лечения сахарного диабета и комбинированное лекарственное средство
RU2526153C2 (ru)	2014-08-20	Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
RU2523451C2 (ru)	2014-07-20	Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2525155C2 (ru)	2014-08-10	Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
RU2543332C2 (ru)	2015-02-27	Лекарственное средство для коррекции эндотелиальной дисфункции
RU2523557C2 (ru)	2014-07-20	Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии
RU2542414C2 (ru)	2015-02-20	Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2525156C2 (ru)	2014-08-10	Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
RU2441023C1 (ru)	2012-01-27	Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2651005C2 (ru)	2018-04-18	Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция
RU2531049C2 (ru)	2014-10-20	Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы

Legal Events

Date	Code	Title	Description
2019-02-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application